Literature DB >> 20194601

The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis.

Calvin C Daniels1, Patricia Coan, Janice King, Joanetha Hale, Kimberly A Benton, David E Briles, Susan K Hollingshead.   

Abstract

Pneumococcal surface protein A (PspA) and PspC of Streptococcus pneumoniae are surface virulence proteins that interfere with complement deposition and elicit protective immune responses. The C-terminal halves of PspA and PspC have some structural similarity and contain highly cross-reactive proline-rich (PR) regions. In many PR regions of PspA and PspC, there exists an almost invariant nonproline block (NPB) of about 33 amino acids. Neither the PR regions nor their NPB exhibit the alpha-helical structure characteristic of much of the protection-eliciting N-terminal portions of PspA and PspC. Prior studies of PspA and PspC as immunogens focused primarily on the alpha-helical regions of these molecules that lack the PR and NPB regions. This report shows that immunization with recombinant PR (rPR) molecules and passive immunization with monoclonal antibodies reactive with either NPB or PR epitopes are protective against infection in mice. PR regions of both PspA and PspC were antibody accessible on the pneumococcal surface. Our results indicate that while PspA could serve as a target of these protective antibodies in invasive infections, PspC might not. When antibody responses to rPR immunogens were evaluated by using flow cytometry to measure antibody binding to live pneumococci, it was observed that the mice that survived subsequent challenge produced significantly higher levels of antibodies reactive with exposed PR epitopes than the mice that became moribund. Due to their conservation and cross-reactivity, the PR regions and NPB regions represent potential vaccine targets capable of eliciting cross-protection immunity against pneumococcal infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20194601      PMCID: PMC2863538          DOI: 10.1128/IAI.01199-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae.

Authors:  S K Hollingshead; R Becker; D E Briles
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

2.  Complete genome sequence of a virulent isolate of Streptococcus pneumoniae.

Authors:  H Tettelin; K E Nelson; I T Paulsen; J A Eisen; T D Read; S Peterson; J Heidelberg; R T DeBoy; D H Haft; R J Dodson; A S Durkin; M Gwinn; J F Kolonay; W C Nelson; J D Peterson; L A Umayam; O White; S L Salzberg; M R Lewis; D Radune; E Holtzapple; H Khouri; A M Wolf; T R Utterback; C L Hansen; L A McDonald; T V Feldblyum; S Angiuoli; T Dickinson; E K Hickey; I E Holt; B J Loftus; F Yang; H O Smith; J C Venter; B A Dougherty; D A Morrison; S K Hollingshead; C M Fraser
Journal:  Science       Date:  2001-07-20       Impact factor: 47.728

3.  Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA.

Authors:  A D Ogunniyi; M C Woodrow; J T Poolman; J C Paton
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

4.  Characterization of binding of human lactoferrin to pneumococcal surface protein A.

Authors:  A Håkansson; H Roche; S Mirza; L S McDaniel; A Brooks-Walter; D E Briles
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

5.  Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae.

Authors:  Priya Balachandran; Alexis Brooks-Walter; Anni Virolainen-Julkunen; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

6.  Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.

Authors:  D E Briles; S K Hollingshead; J King; A Swift; P A Braun; M K Park; L M Ferguson; M H Nahm; G S Nabors
Journal:  J Infect Dis       Date:  2000-11-08       Impact factor: 5.226

7.  Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules.

Authors:  G S Nabors; P A Braun; D J Herrmann; M L Heise; D J Pyle; S Gravenstein; M Schilling; L M Ferguson; S K Hollingshead; D E Briles; R S Becker
Journal:  Vaccine       Date:  2000-03-06       Impact factor: 3.641

8.  Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model.

Authors:  Hazeline Roche; Anders Håkansson; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

9.  Allelic variation in the highly polymorphic locus pspC of Streptococcus pneumoniae.

Authors:  Francesco Iannelli; Marco R Oggioni; Gianni Pozzi
Journal:  Gene       Date:  2002-02-06       Impact factor: 3.688

10.  The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia.

Authors:  A Brooks-Walter; D E Briles; S K Hollingshead
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

View more
  41 in total

Review 1.  Recent advances in pneumococcal peptidoglycan biosynthesis suggest new vaccine and antimicrobial targets.

Authors:  Lok-To Sham; Ho-Ching T Tsui; Adrian D Land; Skye M Barendt; Malcolm E Winkler
Journal:  Curr Opin Microbiol       Date:  2012-01-24       Impact factor: 7.934

2.  PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine.

Authors:  Christina M Croney; Mamie T Coats; Moon H Nahm; David E Briles; Marilyn J Crain
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

3.  Immunization with a ZmpB-based protein vaccine could protect against pneumococcal diseases in mice.

Authors:  Yi Gong; Wenchun Xu; Yali Cui; Xuemei Zhang; Run Yao; Dairong Li; Hong Wang; Yujuan He; Ju Cao; Yibing Yin
Journal:  Infect Immun       Date:  2010-11-22       Impact factor: 3.441

4.  Free Sialic Acid Acts as a Signal That Promotes Streptococcus pneumoniae Invasion of Nasal Tissue and Nonhematogenous Invasion of the Central Nervous System.

Authors:  Brandon L Hatcher; Joanetha Y Hale; David E Briles
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

Review 5.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

6.  Discovery of Immunodominant B Cell Epitopes within Surface Pneumococcal Virulence Proteins in Pediatric Patients with Invasive Pneumococcal Disease.

Authors:  Theano Lagousi; John Routsias; Christina Piperi; Athanassios Tsakris; George Chrousos; Maria Theodoridou; Vana Spoulou
Journal:  J Biol Chem       Date:  2015-09-22       Impact factor: 5.157

7.  Prevalence of PspA families and pilus islets among Streptococcus pneumoniae colonizing children before and after universal use of pneumococcal conjugate vaccines in Brazil.

Authors:  Patricia Alice Knupp-Pereira; Nayara Torres Cardoso Marques; Lúcia Martins Teixeira; Helvécio Cardoso Corrêa Póvoa; Felipe Piedade Gonçalves Neves
Journal:  Braz J Microbiol       Date:  2019-12-04       Impact factor: 2.476

8.  Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins.

Authors:  Eliane N Miyaji; Cintia F M Vadesilho; Maria Leonor S Oliveira; André Zelanis; David E Briles; Paulo L Ho
Journal:  Clin Vaccine Immunol       Date:  2014-12-17

Review 9.  Panel 6: Vaccines.

Authors:  Stephen I Pelton; Melinda M Pettigrew; Stephen J Barenkamp; Fabrice Godfroid; Carlos G Grijalva; Amanda Leach; Janak Patel; Timothy F Murphy; Sanja Selak; Lauren O Bakaletz
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

Review 10.  A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens.

Authors:  Calvin C Daniels; P David Rogers; Chasity M Shelton
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.